Literature DB >> 27464761

Novel Instruments for the Implementation of Electrochemotherapy Protocols: From Bench Side to Veterinary Clinic.

Enrico P Spugnini1, Stefano Fais2, Tommaso Azzarito2, Alfonso Baldi1.   

Abstract

Electrochemotherapy (ECT) is a medical strategy that allows an increased efficacy of chemotherapy agents after the application of permeabilizing electric pulses having appropriate characteristics (form, voltage, frequency). In the past 10 years, the clinical efficacy of this therapeutic approach in several spontaneous models of tumors in animals has been shown. Moreover, some of the molecular and cellular mechanisms responsible for this phenomenon have been elucidated. Our group has been deeply involved in the development of new ECT protocols for companion animals, implementing the use of the technique as first line treatment, and evaluating different chemotherapy agents in laboratory animals as well as pets. This article summarizes the most important advances in veterinary ECT, including the development of novel equipment, therapeutic protocols, and their translation to humans. J. Cell. Physiol. 232: 490-495, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27464761     DOI: 10.1002/jcp.25505

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Preliminary assessment of electrochemotherapy feasibility in dogs with vesical transitional cell carcinoma.

Authors:  Denner Santos Dos Anjos; Rafaela Guedes Buosi; Isadora Roratto; Luciane Dos Reis Mesquita; Oscar Rodrigo Sierra Matiz; Carlos Eduardo Fonseca-Alves; Enrico Pierluigi Spugnini
Journal:  Vet Res Forum       Date:  2020-09-15       Impact factor: 1.054

2.  Isolated limb perfusion electrochemotherapy for the treatment of an advanced squamous cell carcinoma of the hoof in a mare.

Authors:  Enrico Pierluigi Spugnini; Carlo Bolaffio; Licia Scacco; Alfonso Baldi
Journal:  Open Vet J       Date:  2017-06-28

3.  Ultrasound guided electrochemotherapy for the treatment of a clear cell thymoma in a cat.

Authors:  Enrico Pierluigi Spugnini; Francesco Menicagli; Michela Pettorali; Alfonso Baldi
Journal:  Open Vet J       Date:  2017-03-08

4.  Successful treatment of plantar warts with intralesional bleomycin and electroporation: pilot prospective study.

Authors:  Paola Pasquali; Azael Freites-Martinez; Salvador Gonzalez; Enrico P Spugnini; Alfonso Baldi
Journal:  Dermatol Pract Concept       Date:  2017-07-31

5.  Adjuvant electrochemotherapy with bleomycin and cisplatin combination for canine soft tissue sarcomas: A study of 30 cases.

Authors:  Enrico P Spugnini; Bruno Vincenzi; Bruno Amadio; Alfonso Baldi
Journal:  Open Vet J       Date:  2019-03-25

6.  Combination of bleomycin and cisplatin as adjuvant electrochemotherapy protocol for the treatment of incompletely excised feline injection-site sarcomas: A retrospective study.

Authors:  Enrico P Spugnini; Bruno Vincenzi; Francesca Carocci; Chiara Bonichi; Francesco Menicagli; Alfonso Baldi
Journal:  Open Vet J       Date:  2020-07-31

Review 7.  Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.

Authors:  Alfonso Baldi; Antonio De Luca; Patrizia Maiorano; Costantino D'Angelo; Antonio Giordano
Journal:  Int J Mol Sci       Date:  2020-03-07       Impact factor: 5.923

8.  Definition of a Novel Plasmid-Based Gene Transfection Protocol of Mammalian Skeletal Muscles by Means of In Vivo Electroporation.

Authors:  Enrico P Spugnini; Manuel Scimeca; Bruno Amadio; Giancarlo Cortese; Maurizio Fanciulli; Bruno Vincenzi; Antonio De Luca; Alfonso Baldi
Journal:  Int J Mol Sci       Date:  2020-09-05       Impact factor: 5.923

9.  Comparison of two different doses of bleomycin in electrochemotherapy protocols for feline cutaneous squamous cell carcinoma nonsegregated from ultraviolet light exposure.

Authors:  Andrigo B De Nardi; Carlos E Fonseca-Alves; Denner S Dos Anjos; Oscar R Sierra; Enrico P Spugnini
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.